Key statistics
On Tuesday, Acrivon Therapeutics Inc (ACRV:NMQ) closed at 7.00, 119.44% above the 52 week low of 3.19 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.96 |
---|---|
High | 7.10 |
Low | 6.91 |
Bid | 6.90 |
Offer | 7.40 |
Previous close | 6.94 |
Average volume | 79.99k |
---|---|
Shares outstanding | 30.97m |
Free float | 18.68m |
P/E (TTM) | -- |
Market cap | 214.95m USD |
EPS (TTM) | -2.77 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
- Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
- Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
- Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
- Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
- Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
- Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
- Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
- Acrivon Therapeutics Announces $130 Million Private Placement Financing
More ▼